Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • William Blair and other analysts maintain bullish stance, consensus price target USD 9.12.
  • Quarterly earnings and revenue beat expectations despite share price near 52-week low.

William Blair reiterated its outperform rating on Autolus Therapeutics (NASDAQ:AUTL), reinforcing a broadly positive analyst sentiment for the clinical-stage biotech firm. Needham & Company echoed this view with a “buy” rating and a USD 10.00 price target, while Wells Fargo trimmed its target to USD 5.00 but maintained an overweight rating. Wall Street Zen upgraded its rating from sell to hold, contributing to a consensus analyst Buy rating for AUTL with a target price of USD 9.12.

Shares of AUTL opened recently at USD 1.56, positioning the stock near its 52-week low of USD 1.11 and well below the high of USD 5.00. For the quarter ending August 12th, the company posted an EPS loss of USD 0.18, surpassing analyst expectations by USD 0.06. Quarterly revenue was USD 13.50 million, also exceeding estimates.

Major institutional shareholders increased stakes considerably during the year. Armistice Capital LLC raised its holding by nearly 20%, now owning 11 million shares. Wellington Management Group LLP and Bank of America Corp DE also significantly expanded their positions. Collectively, hedge funds and institutional investors now hold over 72% of outstanding shares, underscoring strong market confidence in Autolus’s strategic direction.

While Autolus remains in its developmental phase with ongoing losses, exceeding earnings estimates and growing institutional backing paint a cautiously optimistic outlook.